Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.31
ERFSF's Cash to Debt is ranked lower than
81% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. ERFSF: 0.31 )
Ranked among companies with meaningful Cash to Debt only.
ERFSF' s 10-Year Cash to Debt Range
Min: 0.23  Med: 0.41 Max: No Debt
Current: 0.31
Equity to Asset 0.35
ERFSF's Equity to Asset is ranked lower than
81% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. ERFSF: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
ERFSF' s 10-Year Equity to Asset Range
Min: 0.15  Med: 0.31 Max: 0.35
Current: 0.35
0.15
0.35
F-Score: 4
Z-Score: 3.40
WACC vs ROIC
3.25%
8.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 7.19
ERFSF's Operating margin (%) is ranked higher than
67% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. ERFSF: 7.19 )
Ranked among companies with meaningful Operating margin (%) only.
ERFSF' s 10-Year Operating margin (%) Range
Min: 1.6  Med: 7.27 Max: 12.76
Current: 7.19
1.6
12.76
Net-margin (%) 5.61
ERFSF's Net-margin (%) is ranked higher than
71% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. ERFSF: 5.61 )
Ranked among companies with meaningful Net-margin (%) only.
ERFSF' s 10-Year Net-margin (%) Range
Min: -1.76  Med: 4.47 Max: 6.68
Current: 5.61
-1.76
6.68
ROE (%) 16.47
ERFSF's ROE (%) is ranked higher than
84% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. ERFSF: 16.47 )
Ranked among companies with meaningful ROE (%) only.
ERFSF' s 10-Year ROE (%) Range
Min: -7.27  Med: 14.15 Max: 20.5
Current: 16.47
-7.27
20.5
ROA (%) 4.68
ERFSF's ROA (%) is ranked higher than
72% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. ERFSF: 4.68 )
Ranked among companies with meaningful ROA (%) only.
ERFSF' s 10-Year ROA (%) Range
Min: -1.62  Med: 4.55 Max: 6.12
Current: 4.68
-1.62
6.12
ROC (Joel Greenblatt) (%) 31.42
ERFSF's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. ERFSF: 31.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ERFSF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 8.45  Med: 34.21 Max: 66.78
Current: 31.42
8.45
66.78
Revenue Growth (3Y)(%) 18.40
ERFSF's Revenue Growth (3Y)(%) is ranked higher than
87% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. ERFSF: 18.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ERFSF' s 10-Year Revenue Growth (3Y)(%) Range
Min: 8.2  Med: 18.55 Max: 38.1
Current: 18.4
8.2
38.1
EBITDA Growth (3Y)(%) 14.70
ERFSF's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. ERFSF: 14.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ERFSF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -0.8  Med: 20.00 Max: 64.4
Current: 14.7
-0.8
64.4
EPS Growth (3Y)(%) 11.80
ERFSF's EPS Growth (3Y)(%) is ranked higher than
69% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. ERFSF: 11.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ERFSF' s 10-Year EPS Growth (3Y)(%) Range
Min: 10.3  Med: 35.00 Max: 341.4
Current: 11.8
10.3
341.4
» ERFSF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ERFSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 60.48
ERFSF's P/E(ttm) is ranked lower than
88% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.70 vs. ERFSF: 60.48 )
Ranked among companies with meaningful P/E(ttm) only.
ERFSF' s 10-Year P/E(ttm) Range
Min: 15.49  Med: 50.38 Max: 70.64
Current: 60.48
15.49
70.64
Forward P/E 33.90
ERFSF's Forward P/E is ranked lower than
76% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. ERFSF: 33.90 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 59.30
ERFSF's PE(NRI) is ranked lower than
88% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. ERFSF: 59.30 )
Ranked among companies with meaningful PE(NRI) only.
ERFSF' s 10-Year PE(NRI) Range
Min: 15.49  Med: 43.76 Max: 70.27
Current: 59.3
15.49
70.27
P/B 6.90
ERFSF's P/B is ranked lower than
79% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. ERFSF: 6.90 )
Ranked among companies with meaningful P/B only.
ERFSF' s 10-Year P/B Range
Min: 1.99  Med: 5.19 Max: 11.35
Current: 6.9
1.99
11.35
P/S 3.40
ERFSF's P/S is ranked lower than
54% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. ERFSF: 3.40 )
Ranked among companies with meaningful P/S only.
ERFSF' s 10-Year P/S Range
Min: 0.66  Med: 2.11 Max: 3.55
Current: 3.4
0.66
3.55
PFCF 61.71
ERFSF's PFCF is ranked lower than
72% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.00 vs. ERFSF: 61.71 )
Ranked among companies with meaningful PFCF only.
ERFSF' s 10-Year PFCF Range
Min: 15.19  Med: 46.42 Max: 133.72
Current: 61.71
15.19
133.72
POCF 22.56
ERFSF's POCF is ranked lower than
55% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.49 vs. ERFSF: 22.56 )
Ranked among companies with meaningful POCF only.
ERFSF' s 10-Year POCF Range
Min: 6.58  Med: 17.34 Max: 33.45
Current: 22.56
6.58
33.45
EV-to-EBIT 49.63
ERFSF's EV-to-EBIT is ranked lower than
85% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.91 vs. ERFSF: 49.63 )
Ranked among companies with meaningful EV-to-EBIT only.
ERFSF' s 10-Year EV-to-EBIT Range
Min: 11  Med: 26.70 Max: 95.6
Current: 49.63
11
95.6
PEG 2.72
ERFSF's PEG is ranked higher than
54% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. ERFSF: 2.72 )
Ranked among companies with meaningful PEG only.
ERFSF' s 10-Year PEG Range
Min: 0.55  Med: 1.83 Max: 5.97
Current: 2.72
0.55
5.97
Shiller P/E 101.59
ERFSF's Shiller P/E is ranked lower than
89% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.93 vs. ERFSF: 101.59 )
Ranked among companies with meaningful Shiller P/E only.
ERFSF' s 10-Year Shiller P/E Range
Min: 38.24  Med: 81.72 Max: 121.54
Current: 101.59
38.24
121.54
Current Ratio 1.38
ERFSF's Current Ratio is ranked lower than
79% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. ERFSF: 1.38 )
Ranked among companies with meaningful Current Ratio only.
ERFSF' s 10-Year Current Ratio Range
Min: 1.14  Med: 1.38 Max: 1.92
Current: 1.38
1.14
1.92
Quick Ratio 1.33
ERFSF's Quick Ratio is ranked lower than
72% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. ERFSF: 1.33 )
Ranked among companies with meaningful Quick Ratio only.
ERFSF' s 10-Year Quick Ratio Range
Min: 1.02  Med: 1.33 Max: 1.86
Current: 1.33
1.02
1.86
Days Sales Outstanding 83.21
ERFSF's Days Sales Outstanding is ranked lower than
69% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. ERFSF: 83.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
ERFSF' s 10-Year Days Sales Outstanding Range
Min: 3.69  Med: 83.21 Max: 100.06
Current: 83.21
3.69
100.06

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.44
ERFSF's Dividend Yield is ranked lower than
93% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. ERFSF: 0.44 )
Ranked among companies with meaningful Dividend Yield only.
ERFSF' s 10-Year Dividend Yield Range
Min: 0.16  Med: 0.43 Max: 12.24
Current: 0.44
0.16
12.24
Dividend Payout 0.24
ERFSF's Dividend Payout is ranked higher than
74% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.33 vs. ERFSF: 0.24 )
Ranked among companies with meaningful Dividend Payout only.
ERFSF' s 10-Year Dividend Payout Range
Min: 0.06  Med: 0.21 Max: 5.79
Current: 0.24
0.06
5.79
Dividend growth (3y) 81.70
ERFSF's Dividend growth (3y) is ranked higher than
95% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.50 vs. ERFSF: 81.70 )
Ranked among companies with meaningful Dividend growth (3y) only.
ERFSF' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: 100
Current: 81.7
0
100
Yield on cost (5-Year) 6.45
ERFSF's Yield on cost (5-Year) is ranked higher than
93% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. ERFSF: 6.45 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ERFSF' s 10-Year Yield on cost (5-Year) Range
Min: 2.29  Med: 6.16 Max: 175.33
Current: 6.45
2.29
175.33
Share Buyback Rate -0.80
ERFSF's Share Buyback Rate is ranked higher than
71% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.70 vs. ERFSF: -0.80 )
Ranked among companies with meaningful Share Buyback Rate only.
ERFSF' s 10-Year Share Buyback Rate Range
Min: 0.5  Med: -1.40 Max: -3
Current: -0.8

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.50
ERFSF's Price/Projected FCF is ranked lower than
73% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. ERFSF: 3.50 )
Ranked among companies with meaningful Price/Projected FCF only.
ERFSF' s 10-Year Price/Projected FCF Range
Min: 1.56  Med: 2.58 Max: 6.25
Current: 3.5
1.56
6.25
Price/DCF (Earnings Based) 7.56
ERFSF's Price/DCF (Earnings Based) is ranked lower than
100% of the 15 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. ERFSF: 7.56 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.58
ERFSF's Price/Median PS Value is ranked lower than
83% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. ERFSF: 1.58 )
Ranked among companies with meaningful Price/Median PS Value only.
ERFSF' s 10-Year Price/Median PS Value Range
Min: 0.39  Med: 0.64 Max: 1.22
Current: 1.58
0.39
1.22
Price/Peter Lynch Fair Value 3.73
ERFSF's Price/Peter Lynch Fair Value is ranked lower than
85% of the 26 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.96 vs. ERFSF: 3.73 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ERFSF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.16  Med: 1.82 Max: 4.43
Current: 3.73
1.16
4.43
Earnings Yield (Greenblatt) (%) 2.06
ERFSF's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. ERFSF: 2.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ERFSF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1  Med: 3.70 Max: 9.1
Current: 2.06
1
9.1
Forward Rate of Return (Yacktman) (%) 17.22
ERFSF's Forward Rate of Return (Yacktman) (%) is ranked higher than
73% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. ERFSF: 17.22 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ERFSF' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 9  Med: 19.30 Max: 46.7
Current: 17.22
9
46.7

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 1,834 1,956 2,074
EPS($) 8.58 9.24 10.54
EPS without NRI($) 8.58 9.24 10.54

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:ERF.France, ERF.Switzerland, 0MV5.UK, ERFNV.France, ESF.Germany,
Eurofins Scientific SE founded in 1987, is engaged in food and pharmaceutical products testing. It services include food & feed testing, pharma services, pharma product testing, forensics & applied genetics,environmental services, agrosciences services, genomic services, forensic services and REACH services. It operates over 190 laboratories across 36 countries. The Group is organised on a worldwide basis into one main business segment: Analytical testing. It operates in seven main geographical areas. These are Benelux, France, Germany, North America, Nordic countries, UK and Ireland, and Other countries.
» More Articles for ERFSF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK